Prescriptions for low testosterone (or Low-T) therapy have more than doubled since 2006. In 2011, 5.3 million testosterone prescriptions were written in the United States. It’s estimated that 13.8 million American men now experience the effects of lowered testosterone levels.

And Big Pharma companies are urging these men with aggressive marketing tactics to seek treatment for not only symptoms of “Low T,” but also low energy, sagging muscles, decreased libido, mood changes, and emotional issues, to name a few.

The largest Big Pharma companies that make and market Low T medical products are:

Abbvie, Inc. (a wholly owned subsidiary of Abbott Labs), which makes the name brand AndroGel® testosterone gel.
Elli Lilly and Company, which makes the name brand testosterone underarm gel Axiron®.
There are also a group of smaller Big Pharma companies that manufacture and sell prescription testosterone. They are:

Actavis, Inc., who markets Androderm®
Endo Pharmaceuticals, who markets Fortesta® Testosterone Gel
Auxilium Pharmaceuticals, Inc., who markets Testim Testosterone Gel
BioSante/Teva, who markets Bio-T-Gel
Two recent studies show that testosterone therapy in men over 65 doubled their risk of heart attack and tripled the risk of cardio events for men under 65 with pre-existing heart disease. Injuries can occur within 90 days of exposure from testosterone made of topical gel, transdermal patch, buccal system (gum), and injection.

The FDA took note of the recent two studies and the growing number of men who use testosterone therapy. The agency has decided to reassess the safety of testosterone supplementation evaluating the risk of stroke, heart attack, and death from testosterone medical products.

Significantly, the FDA only approved testosterone products for men with low testosterone levels who also have an associated medical condition.

More to come on this story as it develops.